Governor Kathy Hochul announced that Garonit Pharmaceutical, Inc., a global manufacturer of antiseptic products and health care solutions, will establish a state-of-the-art, 200,000-square-foot pharmaceutical manufacturing facility in New Windsor, Orange County. With a $46.1 million investment, the facility will become the world’s largest chlorhexidine gluconate manufacturing operation, producing antiseptic products essential for surgical disinfection and infection prevention in hospitals worldwide. New York State is supporting this project with $3.8 million, including up to $3.5 million through the Excelsior Jobs Program and a $300,000 Mid-Hudson Regional Economic Development Council capital grant. The project marks a major milestone in New York’s strategy to grow its life sciences sector and expand domestic pharmaceutical manufacturing.
“New York is leading the way in reshoring pharmaceutical manufacturing, strengthening supply chains and creating high-quality jobs — and Garonit Pharmaceutical’s decision to invest in Orange County is proof of that progress,” Governor Hochul said. “This world-class facility will produce essential antiseptic products used in surgical and hospital settings around the globe, further positioning our state as a leader in the life sciences sector. With this investment, we are not only creating good-paying jobs but also reaffirming that New York is where innovation and opportunity meet.”
Empire State Development President, CEO, and Commissioner Hope Knight said, “Garonit Pharmaceutical’s expansion into New York reflects the confidence that global companies have in our state’s workforce, infrastructure, and innovation ecosystem. The Mid-Hudson region’s strategic location, robust infrastructure, and proximity to world-class transportation networks make it an ideal location for advanced manufacturing operations. This project will generate long-term economic benefits and position the region for continued growth in the pharmaceutical sector.”
Garonit Pharmaceutical Inc. Owner Rohit Garg said, ”As the U.S.-based owner of an API manufacturing company, I have long aspired to produce finished pharmaceutical products here in the United States. This achievement has been made possible through the invaluable support and collaboration of dedicated teams of The State of New York, Orange County, and City leaders of New Windsor.”
Garonit Pharmaceutical Inc. Owner Nitin Garg said, “In designing our new manufacturing facility, we were thrilled to incorporate a dedicated technology research and development center in New Windsor, which will serve as a hub for formulating new FDA-regulated products. This milestone is strengthened by our collaboration with SUNY Orange, as we work together to develop programs that bridge operational excellence with advanced research and development.”
Garonit Pharmaceutical was founded in 1994 in Mumbai, India and specializes in antiseptic ingredients and healthcare solutions for medical facilities worldwide. As Garonit expanded globally, it built additional manufacturing capabilities to better serve customers. Today, the company operates manufacturing sites in the United States and India, with additional operations in the United Kingdom, Hong Kong and Japan.
The new facility, strategically located near Stewart International Airport, will serve as the world’s largest chlorhexidine gluconate manufacturing operation and will manufacture antiseptic products, including both ANDA and NDA formulations that are subject to full U.S. Food and Drug Administration approval. The products to be manufactured at this site are commonly used in hospital settings, particularly in surgical environments, with the initial product portfolio focusing on antiseptics designed to maintain sterility and support cleanliness during a wide range of medical procedures. The 200,000-square-foot facility will feature advanced production lines for liquid finished dosage forms and a state-of-the-art laboratory equipped with advanced analytical equipment for quality testing and research. The facility will also house a fully equipped research and development center dedicated to the development of both Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms, with a focus on bringing innovative new drugs to the U.S. market.
Construction is scheduled to begin in Q1 2026, with production operations anticipated to start in January 2027. The project will create an estimated 100 to 150 construction jobs during the build phase, and the 100 full-time pharmaceutical positions will include production, quality assurance, warehouse, R&D, administration and logistics, management, and sales roles. The facility will export products to existing customers across North America, Europe, Japan, Australia, and other global markets with growing demand for these critical pharmaceutical ingredients.
Garonit Pharmaceutical has begun collaborating with SUNY Orange Community College to develop specialized training programs that will prepare local residents for these high-skill positions. The partnership includes FDA compliance training programs and specific associates degree programs that provide opportunities to work in pharmaceutical laboratories. Garonit will also offer positions requiring bachelor’s, master’s, and PhD qualifications, allowing employees to work while pursuing advanced degrees. This workforce development initiative will create a sustainable pipeline of qualified workers while providing career advancement opportunities for residents of Orange County and the broader Mid-Hudson region.
